US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
JP4579351B2
(ja)
|
1996-12-03 |
2010-11-10 |
スローン−ケッタリング インスティトュート フォア キャンサー リサーチ |
エポチロンの合成とその中間体及びその類似物並びにその使用
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
FR2775187B1
(fr)
*
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
US6596875B2
(en)
|
2000-02-07 |
2003-07-22 |
James David White |
Method for synthesizing epothilones and epothilone analogs
|
US20050042275A1
(en)
*
|
1999-08-04 |
2005-02-24 |
Jean-Claude Sonntag |
Epothilone compositions
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
US6489314B1
(en)
*
|
2001-04-03 |
2002-12-03 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
RU2003128311A
(ru)
*
|
2001-02-20 |
2005-03-10 |
Бристол-Маерс Сквибб Компани (Us) |
Способ лечения резистентных опухолей с применением аналогов эпотилона
|
KR100848197B1
(ko)
*
|
2001-02-27 |
2008-07-24 |
노파르티스 아게 |
신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물
|
SK287334B6
(sk)
*
|
2001-03-19 |
2010-07-07 |
Novartis Ag |
Kombinácia protihnačkového činidla a epotilónu alebo jeho derivátu, farmaceutická kompozícia a obchodné balenie, ktoré ju obsahujú, a jej použitie
|
US6906188B2
(en)
*
|
2001-04-30 |
2005-06-14 |
State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Method for synthesizing epothilones and epothilone analogs
|
US20070203346A1
(en)
*
|
2001-04-30 |
2007-08-30 |
Oregon State University |
Method for synthesizing epothilones and epothilone analogs
|
TWI315982B
(en)
*
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
TWI287986B
(en)
*
|
2001-12-13 |
2007-10-11 |
Novartis Ag |
Use of Epothilones for the treatment of the carcinoid syndrome
|
PL369670A1
(en)
*
|
2002-01-14 |
2005-05-02 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
SI1503756T1
(sl)
*
|
2002-05-01 |
2010-01-29 |
Novartis Ag |
Epotilonski derivat za zdravljenje hepatoma in drugih rakavih bolezni
|
JP2006514681A
(ja)
*
|
2002-05-20 |
2006-05-11 |
コーザン バイオサイエンシス インコーポレイテッド |
エポチロンdの投与方法
|
US7649006B2
(en)
*
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
DE60330407D1
(de)
|
2002-08-23 |
2010-01-14 |
Sloan Kettering Inst Cancer |
Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
|
PT1553938E
(pt)
*
|
2002-10-15 |
2007-03-30 |
Univ Louisiana State |
Utilização de derivados de epotilona para o tratamento do hiperparatiroidismo
|
ATE534649T1
(de)
*
|
2003-05-15 |
2011-12-15 |
Arqule Inc |
Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
|
WO2005000292A1
(en)
*
|
2003-06-27 |
2005-01-06 |
Novartis Ag |
Cancer treatment with epothilones
|
CN1870995A
(zh)
*
|
2003-09-02 |
2006-11-29 |
诺瓦提斯公司 |
使用埃坡霉素的癌症治疗
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
US7829560B2
(en)
*
|
2004-07-08 |
2010-11-09 |
Arqule, Inc. |
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
|
JP2008517064A
(ja)
*
|
2004-10-19 |
2008-05-22 |
アークル インコーポレイテッド |
P38mapキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
|
EP1824458A1
(en)
*
|
2004-11-18 |
2007-08-29 |
Bristol-Myers Squibb Company |
Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
|
CA2607940C
(en)
|
2005-05-18 |
2009-12-15 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
ES2637592T3
(es)
|
2006-04-14 |
2017-10-13 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
SG10201407457UA
(en)
|
2006-05-16 |
2014-12-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
BRPI0921862A2
(pt)
*
|
2008-12-05 |
2015-12-29 |
Arqule Inc |
inibidores de raf e seus usos
|
BRPI1012246A2
(pt)
*
|
2009-03-25 |
2016-03-29 |
Novartis Ag |
composição farmacêutica contendo um fármaco e sirna
|
MX340870B
(es)
|
2010-02-12 |
2016-07-27 |
Pharmascience Inc |
Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
|
EP2571525A4
(en)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Compositions and methods for treating autoimmune and other diseases
|